“You must go get your test,” urges Knowles, mom to Beyoncé and Solange. Docs could have found her cancer earlier, she says in her new memoir, “Matriarch.” ...

Nearly three quarters of non-small cell lung cancer (NSCLC) patients with HER2 mutations experienced tumor regression when treated with zongertinib, a novel targeted therapy, according to results from ...

A Liquid Biopsy-based Assay Could Detect Recurrence Prior to Imaging in Patients With Resectable Colorectal Cancer An ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay detected ...

Most people with mismatch repair deficient (dMMR) cancers who used the checkpoint inhibitor Jemperli (dostarlimab) were able to forgo surgery and maintain their quality of life, according to study ...

The American Association for Cancer Research (AACR) today announced the launch of the AACR Trailblazer Cancer Research Grant Program during the Opening Ceremony of the AACR Annual Meeting 2025. This ...

Fred Hutch researchers discover that most transcription factors in budding yeast don’t follow the textbook example of binding close to the genes they regulate.

This is the first study in more than 20 years to show improvement over standard care for patients with locally advanced head and neck cancer.

Pretrained Machine Learning Models May Help Accurately Diagnose Nonmelanoma Skin Cancer in Resource-limited Settings Artificial intelligence models, pretrained on vast datasets, significantly ...

Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib, according to ...

CHICAGO – The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25–30 at the ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term ...